螺内酯作为酒精使用障碍潜在新药:来自啮齿类与人类研究的一致性证据
研究在小鼠饮酒模型和大鼠酒精依赖模型中测试螺内酯效果,并在美国最大整合医疗系统中开展药物流行病学队列研究,分析连续至少60天接受螺内酯与AUDIT-C自报酒精消费变化的关系。啮齿类中螺内酯剂量依赖性减少酒精摄入和操作式自我给药,人类中接受螺内酯者酒精消费下降幅度大于倾向评分匹配的未接受者,基线有害/重度 episodic 饮酒(AUDIT-C≥8)及≥50 mg/天暴露者效应最大。
要点
- 螺内酯剂量依赖性减少雄性和雌性小鼠甜味或非甜味酒精溶液摄入。
- 螺内酯剂量依赖性减少依赖和非依赖雄雌大鼠的操作式酒精自我给药。
- 人类中接受螺内酯者酒精消费下降大于匹配对照,AUDIT-C≥8及≥50 mg/天者效应最大。
核心结论
- 啮齿类和人类研究一致表明螺内酯减少酒精使用,支持其作为酒精使用障碍新药进一步研究。
研究设计与样本
- 小鼠饮酒模型采用 drinking-in-the-dark,大鼠酒精依赖模型采用 vapor exposure。
- 药物流行病学队列研究在美国最大整合医疗系统中开展,比较连续至少60天接受螺内酯者与倾向评分匹配未接受者的AUDIT-C变化。
主要发现
- 螺内酯剂量依赖性减少雄性和雌性小鼠对甜味或非甜味酒精溶液的摄入。
- 螺内酯对无酒精甜味溶液饮用、食物或水摄入、运动协调、酒精诱导共济失调或血酒精水平未观察到效应。
- 螺内酯剂量依赖性减少依赖和非依赖雄雌大鼠的操作式酒精自我给药。
- 人类中接受螺内酯者酒精消费下降幅度大于倾向评分匹配的未接受者。
- 基线有害/重度 episodic 饮酒(AUDIT-C≥8)及暴露≥50 mg/天者效应最大。
关键数值与推荐
- 人类暴露定义为连续至少60天接受螺内酯。
- 基线有害/重度 episodic 饮酒定义为 AUDIT-C≥8。
- 高效应暴露亚组为螺内酯≥50 mg/天。
临床怎么用
- 螺内酯可能作为酒精使用障碍的潜在新药,尤其对基线AUDIT-C≥8且暴露≥50 mg/天者效应更大。
- 临床决策前需进一步研究验证,不应仅凭本观察性证据改变处方。
局限性
- 人类部分为药物流行病学队列研究,非随机对照试验,可能存在残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Evidence suggests that spironolactone, a nonselective mineralocorticoid receptor (MR) antagonist, modulates alcohol seeking and consumption. Therefore, spironolactone may represent a novel pharmacotherapy for alcohol use disorder (AUD). In this study, we tested the effects of spironolactone in a mouse model of alcohol drinking (drinking-in-the-dark) and in a rat model of alcohol dependence (vapor exposure). We also investigated the association between spironolactone receipt for at least 60 continuous days and change in self-reported alcohol consumption, using the Alcohol Use Disorders Identification Test-Consumption (AUDIT-C), in a pharmacoepidemiologic cohort study in the largest integrated healthcare system in the US. Spironolactone dose-dependently reduced the intake of sweetened or unsweetened alcohol solutions in male and female mice. No effects of spironolactone were observed on drinking of a sweet solution without alcohol, food or water intake, motor coordination, alcohol-induced ataxia, or blood alcohol levels. Spironolactone dose-dependently reduced operant alcohol self-administration in dependent and nondependent male and female rats. In humans, a greater reduction in alcohol consumption was observed among those who received spironolactone, compared to propensity score-matched individuals who did not receive spironolactone. The largest effects were among those who reported hazardous/heavy episodic alcohol consumption at baseline (AUDIT-C ≥ 8) and those exposed to ≥ 50 mg/day of spironolactone. These convergent findings across rodent and human studies demonstrate that spironolactone reduces alcohol use and support the hypothesis that this medication may be further studied as a novel pharmacotherapy for AUD.
引用
- Farokhnia M, Rentsch CT, Chuong V, et al. Spironolactone as a potential new pharmacotherapy for alcohol use disorder: convergent evidence from rodent and human studies. Mol Psychiatry. 2022. PMID: 36123420. doi:10.1038/s41380-022-01736-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。